English--千龙网·中国首都网:Lantern Festival: The ‘real’ Chinese Valentine’s Day 元宵节：赏灯约会，这才是真正的情人节 3月2日 16:09 23 oldest words 世界上最古老的已知词语，I, fire, mother等词已是15000岁高龄 2月27日 10:50 English couplets 春节到，贴一副英文春联吧！2月14日 11

PSOARING is Dermavant’s pivotal Phase 3 psoriasis clinical program for tapinarof, which consists of two parallel group studies—PSOARING 1 and PSOARING 2—to evaluate the safety and efficacy of tapinarof cream 1% dosed once daily (QD) for 12 weeks versus vehicle in adult patients aged 18-75 years diagnosed with plaque psoriasis.

The primary endpoint of both studies will be a Physician Global Assessment (PGA) score assessment of “clear” skin (score of 0) or “almost clear” skin (score of 1), plus at least a 2-grade improvement from baseline, at Week 12. Following the 12-week, vehicle-controlled portion of the PSOARING trials, patients will have the option to enroll in a separate, open-label extension study for an additional 40 weeks of treatment.

Sinovant is initially developing lefamulin for community-acquired pneumonia, one of the leading causes of mortality in Mainland China. Due to its novel mechanism of action, low incidence of cross-resistance between other antibacterial agents commonly used to treat community-acquired pneumonia, and low propensity for bacterial resistance to develop, lefamulin has the potential to be used as a first-line empiric monotherapy for the treatment of community-acquired pneumonia.

Lefamulin has successfully completed two global Phase 3 studies in patients with moderate and severe community-acquired pneumonia. Lefamulin has been granted Qualified Infectious Disease Product (QIDP) designation from the US FDA and is currently in preparation for an MAA in Europe.

In June 2019, the China National Medical Products Administration approved Sinovant’s Clinical Trial Application for lefamulin. In August 2019, Sinovant’s partner Nabriva Therapeutics received FDA approval of lefamulin to treat community-acquired bacterial pneumonia.

Sinovant is initially developing derazantinib, a potent, orally administered inhibitor of the fibroblast growth factor receptor (FGFR) family, for the treatment of intrahepatic cholangiocarcinoma (iCCA), a devastating form of biliary tract cancer with high incidence in Greater China and parts of Asia and no approved therapies. In a Phase 1/2 study in patients with iCCA harboring FGFR2 gene fusions, treatment with derazantinib resulted in an objective response rate of 21%, nearly 3 times higher than standard-of-care chemotherapy.

Derazantinib is currently being evaluated in a registration-enabling study in patients with FGFR2 fusion-positive second-line iCCA in the United States and Europe.

Delayed graft function (DGF) is a form of acute kidney injury that manifests postoperatively in 20-30% of renal transplantation patients globally and is associated with a 40% decrease in long-term graft survival. In Greater China, persistent organ shortages have led to greater use of deceased donor kidneys, which is expected to drive increases in observed rates of DGF.

SNV-003 is an investigational small molecule mimetic of hepatocyte growth factor (HGF) being developed by Sinovant in Greater China for DGF.

官方客户端下载 - fjtv.net:2021-6-8 · Dashboard

SNV-003 is an investigational small molecule mimetic of hepatocyte growth factor (HGF) which Sinovant plans to develop in Greater China for Acute Kidney Injury.

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) are a group of common types of infections and include abscesses, cellulitis, and wound infections most commonly caused by gram-positive bacteria. ABSSSIs have placed an increasing burden on healthcare systems worldwide over the last 25 years, in large part due to the increasing spread and persistence of methicillin-resistant S. aureus (MRSA) strains. There were an estimated 14 million ABSSSI cases in China in 2018.

Lefamulin is a novel antibiotic of the pleuromutilin class whose mechanism of action leads to a low cross-resistance profile with other antibacterial agents. Lefamulin is currently in Phase 2 development for the treatment of ABSSSI. In August 2019, Sinovant’s partner Nabriva Therapeutics received FDA approval of lefamulin to treat community-acquired bacterial pneumonia.

广东一网民擅自建立、使用非法定信道进行国际联网 被处罚 ...:2021-1-4 · 2021年12月28日，广东公安执法信息公开平台发布一条行政处罚决定书，内容如下： 行政处罚决定书[2021]1号 被处罚人：朱某某 处罚事由：擅自建立 ...

Naronapride has been evaluated in over 900 subjects in multiple randomized controlled clinical studies and has demonstrated promising results in patients with gastroesophageal reflux disease (GERD), erosive esophagitis (EE), and chronic idiopathic constipation (CIC). Naronapride’s low systemic absorption and high receptor specificity is thought to improve its safety and tolerability profile relative to other members of the class.

雨水：好雨知时节 Rain Water: Good rain knows its time right ...:2021-2-17 · Rain Water, one of the 24 solar terms of China, is arriving. Let’s go through some Chinese poems to experience the feeling of ancient people for rain water in early spring.二十四节气之一的雨水即将到来，正如古诗所云：“好雨知时节”。让我们通过几首 ...

ARU-1801 was developed in the laboratory of Dr. Punam Malik, Director of the Cincinnati Comprehensive Sickle Cell Center at Cincinnati Children’s. Preliminary clinical data from an ongoing Phase 1/2 study of ARU-1801 in patients with sickle cell disease conducted using a reduced-intensity conditioning (RIC) regimen enabled by the unique properties of modified fetal hemoglobin was presented by Dr. Malik in an oral presentation on Monday, December 3^rd, 2018, at the Annual Meeting and Exposition of the American Society of Hematology in San Diego, CA.

AXO-Lenti-PD is an investigational gene therapy for Parkinson’s disease that delivers three genes via a single lentiviral vector to encode a set of critical enzymes required for dopamine synthesis, with the goal of reducing variability and restoring steady levels of dopamine in the brain. The gene therapy aims to provide patient benefit for years following a single administration.

Axovant announced positive 12-month data results from the first cohort of patients in its ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD in January 2020 and announced positive initial 6-month data from the second cohort of patients in February 2020.

CVT-DC-01 is a dendritic cell vaccine being developed for post-remission acute myeloid leukemia. Dendritic cell vaccines are patient-derived therapies in which a patient’s own dendritic cells are loaded with tumor antigens to elicit immune responses against cancerous cells. Different tumor antigens can be loaded into dendritic cells to treat various forms of cancer. As DC vaccines are designed to activate immune responses against tumor antigens over the course of vaccine administration, these therapies may be particularly suitable for cancer patients for whom prevention of disease relapse is the main treatment goal.

Cerdulatinib is a topical dual janus kinase (JAK) and spleen tyrosine kinase (Syk) inhibitor. Dermavant is developing cerdulatinib as a topical therapy for a variety of dermatologic conditions. Dermavant believes that the profile of cerdulatinib is ideal for development in skin diseases where a growing body of evidence suggests that both JAK and Syk are important drivers of disease manifestation.

Tapinarof is an investigational therapeutic aryl hydrocarbon receptor modulating agent (TAMA) for the treatment of psoriasis and atopic dermatitis. It has been evaluated as a topical therapy in multiple Phase 1 and Phase 2 studies involving over 800 human subjects.

In a double-blind, placebo-controlled global phase 2b dose-ranging study that enrolled 247 patients with atopic dermatitis, tapinarof demonstrated clinically meaningful, dose-dependent improvements over vehicle on the primary endpoint of the study. Tapinarof was generally well tolerated. The most frequently reported adverse events were folliculitis, contact dermatitis and the common cold. Efficacy assessments were made on a modified intent-to-treat population.

Warm autoimmune hemolytic anemia (WAIHA) is a rare hematologic disease in which autoantibodies mediate hemolysis, or the destruction of red blood cells. WAIHA approximately affects 42,000 people in the United States and 66,000 people in Europe. The clinical presentation is variable and most commonly includes non-specific symptoms of anemia such as fatigue, weakness, skin paleness, and shortness of breath. Symptoms typically develop chronically over several weeks to months, but rapid progression over a span of days has also been observed.

Immunovant is developing IMVT-1401, a novel, fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor (FcRn), for the treatment of immunoglobulin G (IgG) mediated diseases, such as WAIHA. IMVT-1401 is being developed as a subcutaneous injection, providing a convenient and minimally invasive treatment option for patients.

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease characterized by weakness and fatigue of voluntary muscles. Symptoms typically emerge in the eyes (e.g., drooping eyes, double-vision, blurred vision) and progress into the face, throat, and limbs. MG is a rare disease that affects approximately 65,000 people in the United States and 104,000 people in Europe, with a greater prevalence among younger women and older men.

The chronic nature of MG requires patients to cope with fluctuating symptoms and multiple treatment regimens for management. Persistent muscle weakness associated with MG often negatively interferes with patients’ ability to engage in daily and physical activities, including demands of work, family, and social functions.

Immunovant is developing IMVT-1401, a novel, fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor (FcRn), for the treatment of immunoglobulin (IgG) mediated diseases, such as MG. IMVT-1401 is being developed as a subcutaneous injection, providing a convenient and minimally invasive treatment option for patients.

Thyroid eye disease (TED), also known as Graves’ ophthalmopathy, is an autoimmune disorder that affects the muscles and other tissues around the eyes. TED approximately affects 33,000 people in the United States and 52,000 people in Europe. Moderate-to-severe TED is characterized by swelling and redness of the eyelids, proptosis (protrusion of the eyeball), double vision, and, in severe cases, corneal ulceration and decreased visual acuity.

Immunovant is developing IMVT-1401, a novel, fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor (FcRn), for the treatment of immunoglobulin (IgG) mediated diseases, such as TED. IMVT-1401 is being developed as a subcutaneous injection, providing a convenient and minimally invasive treatment option for patients.